A Study to Investigate Safety, Tolerability, and Pharmaco... | NCT02933580

NCT02933580

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

ID	Type	Description	Link
56136379HPB1003	Other Identifier	Janssen Research & Development, LLC

Status Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Cohort A: JNJ-56136379 (25 mg) or Placebo	Experimental	Participants will receive a single oral dose of 25 milligram (mg) of JNJ-56136379 (1*25-mg tablet) or placebo on Day 1, fasted conditions.	Drug: JNJ-56136379 Other: Placebo
Cohort B: JNJ-56136379 (150 mg) or Placebo	Experimental	Participants will receive a single oral dose of 150 mg of JNJ-56136379 (2* 25-mg tablet and 1*100-mg tablet) or placebo on Day 1, fasted conditions.	Drug: JNJ-56136379 Other: Placebo
Cohort C: JNJ-56136379 (300 mg) or Placebo	Experimental	Participants will receive a single oral dose of 300 mg of JNJ-56136379 (3*100-mg tablet) or placebo on Day 1, fasted conditions.	Drug: JNJ-56136379 Other: Placebo
Cohort D: JNJ-56136379 (600 mg) or Placebo	Experimental	Participants will receive a single oral dose of 600 mg of JNJ-56136379 (6*100-mg tablet) or placebo on Day 1, fasted conditions.	Drug: JNJ-56136379 Other: Placebo

Interventions

Name	Type	Description	Arm Group Labels	Other Names
JNJ-56136379	Drug	Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.	Cohort A: JNJ-56136379 (25 mg) or Placebo Cohort B: JNJ-56136379 (150 mg) or Placebo

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Maximum Observed Plasma Concentration (Cmax)	The Cmax is the maximum observed plasma concentration.	Up to 29 days
Time to Reach Maximum Observed Plasma Concentration (Tmax)	The Tmax is defined as actual sampling time to reach maximum observed plasma analyte concentration.	Up to 29 days
Area Under the Concentration-Time Curve from time 0 to the Time of the Last Measurable non-Below Quantification Limit Concentration (AUC [0-last])	AUC (0-last) is defined as area under the analyte concentration-time curve from time 0 to the time of the last measurable (non-below quantification limit [BQL]) concentration, calculated by linear-linear trapezoidal summation.	Up to 29 days
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])	The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last observed measurable (non-BQL) concentration, and lambda(z) is elimination rate constant; extrapolations of more than 20.00 percent (%) of the total AUC are reported as approximations.	Up to 29 days
Number of Participants With Adverse events as a Measure of Safety and Tolerability		30-35 days after study drug intake (approximately 8 weeks)

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Participant must be a Japanese participant who has resided outside Japan for no more than 10 years and whose parents and grandparents are Japanese as determined by participant's verbal report
Participant must be healthy on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination, medical and surgical history, vital signs, and the results of blood biochemistry, blood coagulation, and hematology tests and a urinalysis performed at screening. If there are abnormalities, the participant may be included only if the investigator judges the abnormalities to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed/signed by the investigator
Participant must have a body mass index (BMI; weight in kilogram [kg] divided by the square of height in meters) of 18.0 to 30.0 kilogram per meter square [kg/m^2], extremes inclusive, and body weight not less than 45.0 kg
Participant must have a normal 12-lead electrocardiogram (ECG) (based on the mean value of the triplicate parameters) at screening including: normal sinus rhythm (heart rate between 45 and 100 beats per minute [bpm], extremes included); QT interval corrected for heart rate according to Fridericia (QTcF) less than or equal to (<=)450 millisecond (ms); QRS interval less than (<)120 ms; PR interval <=220 ms
A female participant (except if permanently sterile), should have a negative serum pregnancy test at screening and all female participants should have a negative urine pregnancy test on Day -1

Exclusion Criteria:

Participant with a past history of cardiac arrhythmias (example [eg], extrasystoli, tachycardia at rest), history of risk factors for Torsade de Pointes syndrome (eg, hypokalemia, family history of long QT Syndrome)
Female participant who is breastfeeding at screening or pregnant at screening or predose
Male participant planning to father a child while enrolled in this study or within 90 days after study drug administration
Participant with current human immunodeficiency virus type 1 (HIV-1) or HIV-2 infection (confirmed by antibodies) at Screening
Participant with current hepatitis A infection (confirmed by hepatitis A antibody immunoglobulin M [IgM]), or hepatitis B virus (HBV) infection (confirmed by HBsAg), or hepatitis C virus (HCV) infection (confirmed by HCV antibody), or hepatitis E infection (confirmed by hepatitis E antibody IgM) at Screening